Objective: To study the clinical efficacy and safety of the treatment of mizolastine combined with total glucosides of paeony for chronic urticaria

and to provide guidance for the future clinical treatment. Method: Eighty-four patients with chronic urticaria were randomized into the control group (10 mg mizolastine

once evening for 4 weeks) and the observation group (based on the control group

added 600 mg total glucosides of paeony capsules

twice daily for 4 weeks) of 42 patients per group. The clinical efficacy

recurrence rate and adverse reactions in the two groups were observed and compared according to the symptom score decreased index (SSRI). Result: Compared with the control group

the effective rate was significantly increased (90.5% vs 71.4%

P<0.05)

the recurrence rate was obviously reduced (42.9% vs 71.4%

P<0.05)

the SSRI scores were significantly decreased after treatment (0.7±0.2 vs 1.3±0.4

P<0.05)

the serum IgE levels were significantly reduced after treatment[(82.5±13.6) vs (102.9±14.3) U·mL-1

P<0.05] in the observation group. There were no obvious adverse reactions in the two groups during the treatment period. Conclusion: The treatment of mizolastine combined with total glucosides of paeony has significant efficacy and high safety for chronic urticaria

which is worthy of clinical promotion.